SelectQuote, Inc. (SLQT): Nasdaq/NYSE listing notice — SelectQuote stock price below $1.00 triggers NYSE non-compliance notice; cure period six months

SelectQuote, Inc.

NYSE notice: avg closing price <$1.00 over 30 consecutive trading days; six-month cure period to regain compliance.
To cure: closing price >=$1.00 on last trading day of any month and 30-day avg >=$1.00.
Company recently reported strong fiscal Q2 2026; executed $415M credit facility extending maturities to 2031.
Projects FY2026 operating cash flow of $25M-$35M; expects meaningful cash flow growth.
Stock continues trading on NYSE during cure period subject to other listing standards.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SelectQuote, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

March 19, 2026, SelectQuote, Inc. (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating that the Company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard. The Company can regain compliance at any time within the six-month cure period fo

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SelectQuote, Inc. filing history →

Source: SEC EDGAR

accession 0001794783-26-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.